Reborn in America, I'm serious about making money.

The sudden suspension of trading in Dahua 36 immediately attracted a lot of attention. With a 50% drop and a surge in trading volume, the sudden suspension immediately sparked a lot of speculation.

The sudden suspension of trading in Dahua 36 Pharmaceutical Co., Ltd. on the Hong Kong Stock Exchange has attracted widespread attention and heated discussion among investors. The news immediately caused a stir in the market.

Investors speculated about the reason for the trading suspension, with some worriedly saying, "This is terrible! Is Dahua 36 going to go bankrupt?"

Such things do happen; some companies may suddenly experience financial problems or be involved in major lawsuits.

However, some investors are optimistic, believing that the suspension of trading may be due to the company having major positive news to announce, such as the successful development of a new product or a large acquisition plan.

Many people share this sentiment, saying with anticipation, "Perhaps this is a rare opportunity; the stock price might skyrocket after trading is suspended!"

Of course, they were some small investors who, seeing the stock drop by 50%, some gamblers bought some shares.

Immediately, various speculations and discussions arose, and the market atmosphere became tense yet heated. Investors inquired everywhere, trying to obtain more information about Dahua 36's trading suspension from various channels.

How can you just say something like that?

In recent days, the board of directors of Dahua 36 has been the subject of much scrutiny, and their actions have been subject to numerous interpretations.

"Director Zhao, our boss has admired you for a long time. We've heard that you've made many contributions to the pharmaceutical industry, and we'd like to invite you for tea."

Director Zhao is one of the directors of Dahua 36 and a professor at Dahua Pharmaceutical College. However, when he heard someone inviting him on the phone, he immediately replied, "I'm sorry, you want to ask why the stock was suspended, right? I don't know either, but our company's production and sales are normal. Please wait for the later announcements."

After Director Zhao finished speaking, he hung up the phone, saying, "These people, asking about these things, we don't even know why, what are they asking for? Damn it."

Other directors encountered the same thing, but they didn't know the reason, so they didn't dare to talk about it. They also didn't dare to accept invitations from their friends. After all, they were experts and professors and couldn't talk nonsense. The company also allowed them to talk nonsense outside, otherwise they would not only be dismissed from the academy, but also lose their jobs, which would be a loss.

With this in mind, they dared not go. Lately, they've been like frightened birds, very anxious. Whenever someone calls, they panic. If they say they don't know, no one will believe them; if they say they do know, they dare not say anything carelessly.

Over the weekend, Dahua 36 announced that it has signed agreements with three North American medical laboratories (***, ***, and ***) to license three major patents. The licensing fee is $300 million, including subsequent royalty payments. The three patents are: a peptide drug for effectively treating tumors (****), a specific drug for treating cardiovascular and cerebrovascular diseases (****), and a weight-loss drug (***)...

This announcement immediately caused a sensation. These three patented drugs are extremely popular. As for their efficacy, it is still unknown. However, the licensing fee alone is three hundred million US dollars, which is an astronomical price.

At this point, someone stepped forward and said that the cost of developing such a new drug is extremely high. For example, it can take several to more than ten years for a North American pharmaceutical company to develop a drug, and the research and development costs can reach hundreds of millions or even billions of dollars. Of course, much of the research is ineffective, so most of the costs are wasted.

The research and development costs involved are estimated to be in the hundreds of millions of dollars.

However, the profits are also very considerable. Don't be fooled by the fact that the $300 million license is particularly expensive. With so many people suffering from cancer now, and considering that it is effective against malignant tumors according to advertising, it means that this product is indeed very powerful. Moreover, cardiovascular diseases will also become more prevalent in the future, making it a drug with a very wide range of applications. In addition, the cost required is also very considerable.

As for weight loss drugs, with the improvement of people's quality of life in the future, obesity will become the norm. It goes without saying how many people in Asia will become obese in the future.

In fact, these drugs can also be counterfeited, but they are all biopharmaceuticals. The processes involved are impossible to replicate, mainly because the bacteria involved require special genetic engineering.

This eliminates the possibility of others imitating these drugs, meaning they may only be produced exclusively by one company. Moreover, the raw materials are shipped directly from North America to mainland China, making them extremely expensive.

Dahua 36 will set up a business company in Hong Kong to be responsible for the import of this raw material.

Once this news was revealed, investors across Hong Kong felt that this thing was absolutely amazing! Once it went public, they would make a fortune.

Another piece of news is that these three categories of drugs have already passed FDA certification in North America and will be launched in Europe and the United States next month; while in mainland China they still need to go through clinical trials before they can be launched. There is no way around this. Imported drugs that meet North American standards may not meet those in mainland China. People are different, and the dosage and effects of drugs are also different.

However, all of this indicates one thing: these three drugs are very good. I've heard that doctors in North America are already eager to prescribe them to their patients.

"I threw away all the Yan family shovels."

"Damn it, I threw them all away too."

"Hehe... I sold it at ten Hong Kong dollars."

……

The whole of Hong Kong is feeling quite conflicted right now. No one expected that a small pharmaceutical company in mainland China could obtain such a cash cow-like patent license. It's simply too shocking.

Moreover, although this authorization costs $300 million, based on the pricing of the new drug, a drug that originally costs 20,000 RMB in North America will cost at least 100,000 RMB in mainland China, which is considered reasonable. With six injections a year, that's 600,000 RMB, which is truly frightening.

However, just as everyone was digesting this, they issued another announcement stating that this polypeptide-based tumor treatment drug will still be sold at the same price as in Europe and the United States on the date of its market launch, without any price increase.

The same applies to cardiovascular and cerebrovascular drugs and weight loss drugs; there will be no price increase, and they may even be cheaper, in order to meet the needs of patients as much as possible.

This news can be considered good news. At least in their view, they can make a living by selling in large quantities at low profit margins. They might not be able to afford 100,000 yuan a time, but they can manage to make 120,000 yuan a year.

The day after the announcement, Dahua 36's stock price surged from HK$10 to HK$44.1, opening sharply higher. It closed at HK$51.5 that day, enjoying immense popularity.